Viravaxx recently developed a simple and robust ELISA-based interaction assay mimicking SARS-CoV-2 binding to its receptor ACE2. The read-out of the assay is an antibody signature to assess protective immunity of patients. The assay supports identification of subjects having developed protective antibodies and screening of candidate vaccines.
Viravaxx uses the assay in an ongoing clinical trial to analyze neutralizing antibody responses in serum samples of 25 COVID-19 convalescent patients. A more than 50% inhibition was found for six sera. An up to 50% inhibition was found for nine sera. No inhibition was found for five sera. Surprisingly, for five sera an enhancement of RBD binding to ACE2 was noted.
Interested in partnering opportunities for our SARS-CoV-2 interaction assay and our COVID-19 vaccine design program? Please reach out to firstname.lastname@example.org.